SEARCH:   Advanced

Blood, 15 August 2008, Vol. 112, No. 4, pp. 1539-1542. Prepublished online as a Blood First Edition Paper on May 23, 2008; DOI 10.1182/blood-2008-02-138867. This Article Full Text (PDF) All Versions of this Article: blood-2008-02-138867v1 112/4/1539    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Choi, S. W. Articles by Levine, J. E. Search for Related Content PubMed PubMed Citation Articles by Choi, S. W. Articles by Levine, J. E. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 12, 2008 Accepted April 30, 2008 Change in plasma Tumor Necrosis Factor Receptor 1 levels in the first week post-myeloablative allogeneic transplant correlates with severity and incidence of GVHD and survival Sung W. Choi, Carrie L. Kitko, Thomas Braun, Sophie Paczesny, Gregory Yanik, Shin Mineishi, Oleg Krijanovski, Dawn Jones, Joel Whitfield, Kenneth Cooke, Raymond J. Hutchinson, James L.M. Ferrara, and John E. Levine* Department of Pediatrics, University of Michigan, Ann Arbor, MI, United States Department of Internal Medicine, Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, MI, United States Department of Biostatistics, University of Michigan, Ann Arbor, MI, United States Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, United States * Corresponding author; email: jelevine{at}med.umich.edu. Acute graft versus host disease (GVHD) remains a significant cause of mortality following hematopoietic cell transplantation (HCT). Tumor necrosis factor-alpha (TNF) mediates GVHD by amplifying donor immune responses to host tissues and by direct toxicity to target organs. We measured TNF Receptor 1 (TNFR1) as a surrogate marker for TNF in 438 recipients of myeloablative HCT pre-transplant and day 7 post-transplant. Increases in TNFR1 levels 2.5 baseline correlated with eventual development of GVHD grade 2-4 (58% vs 32%, p<0.001), and with treatment-related mortality (39% vs 17%, p<0.001). In a multivariate analysis including age, degree of HLA-match, donor type, recipient and donor gender, disease, and status at HCT, the increase in TNFR1 level at day 7 remained a significant predictor for outcome. Measurement of TNFR1 levels early post-transplant provides independent information in advance of important clinical outcomes such as GVHD and death. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: G. Socie and B. R. Blazar Acute graft-versus-host disease: from the bench to the bedside Blood, November 12, 2009; 114(20): 4327 - 4336. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020